Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NMRA |
---|---|---|
09:32 ET | 1210 | 9.23 |
09:34 ET | 455 | 9.135 |
09:36 ET | 100 | 9.22 |
09:39 ET | 100 | 9.22 |
09:41 ET | 3804 | 9.33 |
09:43 ET | 300 | 9.33 |
09:45 ET | 400 | 9.275 |
09:48 ET | 2927 | 9.31 |
09:50 ET | 850 | 9.31 |
09:52 ET | 2598 | 9.4266 |
09:54 ET | 500 | 9.44 |
09:56 ET | 3570 | 9.465 |
09:57 ET | 400 | 9.455 |
09:59 ET | 300 | 9.48 |
10:01 ET | 3836 | 9.36 |
10:03 ET | 5215 | 9.37 |
10:06 ET | 2232 | 9.405 |
10:08 ET | 229 | 9.4 |
10:10 ET | 1725 | 9.42 |
10:12 ET | 400 | 9.43 |
10:14 ET | 19316 | 9.39 |
10:15 ET | 400 | 9.4 |
10:17 ET | 1435 | 9.4 |
10:19 ET | 300 | 9.45 |
10:21 ET | 2961 | 9.46 |
10:24 ET | 793 | 9.4334 |
10:26 ET | 2900 | 9.4201 |
10:28 ET | 715 | 9.45 |
10:30 ET | 7399 | 9.45 |
10:32 ET | 2150 | 9.47 |
10:35 ET | 3170 | 9.4 |
10:37 ET | 3809 | 9.37 |
10:39 ET | 3294 | 9.41 |
10:42 ET | 800 | 9.415 |
10:44 ET | 5750 | 9.4 |
10:46 ET | 510 | 9.4 |
10:48 ET | 5028 | 9.38 |
10:50 ET | 2555 | 9.35 |
10:51 ET | 1129 | 9.36 |
10:53 ET | 2247 | 9.355 |
10:55 ET | 2978 | 9.35 |
10:57 ET | 3004 | 9.36 |
11:00 ET | 3035 | 9.37 |
11:02 ET | 5200 | 9.29 |
11:04 ET | 879 | 9.31 |
11:06 ET | 1448 | 9.31 |
11:08 ET | 3000 | 9.37 |
11:09 ET | 2019 | 9.41 |
11:11 ET | 100 | 9.43 |
11:13 ET | 484 | 9.405 |
11:15 ET | 5081 | 9.365 |
11:18 ET | 2835 | 9.33 |
11:20 ET | 1300 | 9.33 |
11:22 ET | 3834 | 9.35 |
11:24 ET | 400 | 9.34 |
11:26 ET | 616 | 9.37 |
11:27 ET | 6370 | 9.37 |
11:29 ET | 5293 | 9.3685 |
11:31 ET | 3092 | 9.35 |
11:33 ET | 587 | 9.35 |
11:36 ET | 893 | 9.35 |
11:38 ET | 9965 | 9.37 |
11:40 ET | 2606 | 9.37 |
11:42 ET | 500 | 9.39 |
11:44 ET | 717 | 9.38 |
11:45 ET | 2366 | 9.37 |
11:47 ET | 200 | 9.38 |
11:49 ET | 3975 | 9.3616 |
11:51 ET | 1248 | 9.38 |
11:54 ET | 1074 | 9.38 |
11:58 ET | 2502 | 9.4 |
12:00 ET | 1893 | 9.405 |
12:02 ET | 3306 | 9.46 |
12:03 ET | 300 | 9.46 |
12:05 ET | 2755 | 9.44 |
12:07 ET | 689 | 9.43 |
12:09 ET | 2148 | 9.401 |
12:12 ET | 1829 | 9.41 |
12:14 ET | 814 | 9.41 |
12:16 ET | 1755 | 9.41 |
12:18 ET | 300 | 9.41 |
12:20 ET | 5909 | 9.43 |
12:21 ET | 300 | 9.43 |
12:23 ET | 2187 | 9.45 |
12:25 ET | 3173 | 9.47 |
12:27 ET | 1729 | 9.49 |
12:30 ET | 950 | 9.55 |
12:32 ET | 4905 | 9.6 |
12:34 ET | 5828 | 9.58 |
12:36 ET | 8413 | 9.54 |
12:38 ET | 2400 | 9.54 |
12:39 ET | 2590 | 9.51 |
12:41 ET | 1757 | 9.51 |
12:43 ET | 4103 | 9.48 |
12:45 ET | 2709 | 9.51 |
12:48 ET | 6333 | 9.55 |
12:50 ET | 1100 | 9.55 |
12:52 ET | 5652 | 9.555 |
12:54 ET | 1161 | 9.56 |
12:56 ET | 6755 | 9.57 |
12:57 ET | 4494 | 9.54 |
12:59 ET | 597 | 9.53 |
01:01 ET | 4837 | 9.48 |
01:03 ET | 12179 | 9.555 |
01:06 ET | 5294 | 9.58 |
01:08 ET | 1528 | 9.61 |
01:10 ET | 2347 | 9.61 |
01:12 ET | 8740 | 9.57 |
01:14 ET | 472 | 9.57 |
01:15 ET | 1536 | 9.58 |
01:17 ET | 641 | 9.59 |
01:19 ET | 4922 | 9.62 |
01:21 ET | 16965 | 9.48 |
01:24 ET | 841 | 9.48 |
01:26 ET | 2981 | 9.505 |
01:28 ET | 3256 | 9.505 |
01:30 ET | 6770 | 9.53 |
01:32 ET | 433 | 9.53 |
01:33 ET | 1986 | 9.52 |
01:35 ET | 8663 | 9.5 |
01:37 ET | 6096 | 9.48 |
01:39 ET | 4470 | 9.46 |
01:42 ET | 2470 | 9.44 |
01:44 ET | 4564 | 9.46 |
01:46 ET | 1134 | 9.47 |
01:48 ET | 1863 | 9.49 |
01:50 ET | 3964 | 9.49 |
01:51 ET | 3405 | 9.5 |
01:53 ET | 20195 | 9.575 |
01:55 ET | 2346 | 9.55 |
01:57 ET | 7651 | 9.54 |
02:00 ET | 3140 | 9.53 |
02:02 ET | 1914 | 9.565 |
02:04 ET | 4070 | 9.61 |
02:06 ET | 7024 | 9.53 |
02:08 ET | 17651 | 9.5 |
02:09 ET | 9613 | 9.57 |
02:11 ET | 3953 | 9.53 |
02:13 ET | 2334 | 9.515 |
02:15 ET | 14232 | 9.525 |
02:18 ET | 4183 | 9.52 |
02:20 ET | 1026 | 9.52 |
02:22 ET | 3236 | 9.51 |
02:24 ET | 6418 | 9.49 |
02:26 ET | 1453 | 9.5 |
02:27 ET | 900 | 9.5 |
02:29 ET | 9364 | 9.52 |
02:31 ET | 3358 | 9.49 |
02:33 ET | 1600 | 9.49 |
02:36 ET | 1780 | 9.5 |
02:38 ET | 3302 | 9.505 |
02:40 ET | 1500 | 9.51 |
02:42 ET | 3624 | 9.49 |
02:44 ET | 3886 | 9.51 |
02:45 ET | 2496 | 9.505 |
02:47 ET | 3547 | 9.515 |
02:49 ET | 2349 | 9.53 |
02:51 ET | 6113 | 9.5 |
02:54 ET | 3949 | 9.45 |
02:56 ET | 6333 | 9.49 |
02:58 ET | 3278 | 9.5 |
03:00 ET | 5615 | 9.48 |
03:02 ET | 5692 | 9.47 |
03:03 ET | 4248 | 9.471 |
03:05 ET | 10335 | 9.47 |
03:07 ET | 21945 | 9.51 |
03:09 ET | 6113 | 9.495 |
03:12 ET | 14431 | 9.51 |
03:14 ET | 12520 | 9.515 |
03:16 ET | 18636 | 9.55 |
03:18 ET | 8912 | 9.56 |
03:20 ET | 8240 | 9.55 |
03:21 ET | 6952 | 9.55 |
03:23 ET | 10141 | 9.57 |
03:25 ET | 5129 | 9.58 |
03:27 ET | 21115 | 9.61 |
03:30 ET | 14938 | 9.63 |
03:32 ET | 8935 | 9.605 |
03:34 ET | 2213 | 9.61 |
03:36 ET | 14491 | 9.68 |
03:38 ET | 21123 | 9.675 |
03:39 ET | 7094 | 9.67 |
03:41 ET | 17265 | 9.62 |
03:43 ET | 3746 | 9.65 |
03:45 ET | 19841 | 9.61 |
03:48 ET | 3925 | 9.67 |
03:50 ET | 21213 | 9.67 |
03:52 ET | 180638 | 9.82 |
03:54 ET | 66445 | 9.87 |
03:56 ET | 45886 | 9.82 |
03:57 ET | 50721 | 9.81 |
03:59 ET | 64015 | 9.83 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Neumora Therapeutics Inc | 1.6B | -6.4x | --- |
Kura Oncology Inc | 1.6B | -9.5x | --- |
Akero Therapeutics Inc | 1.6B | -7.3x | --- |
Keros Therapeutics Inc | 1.6B | -8.9x | --- |
Edgewise Therapeutics Inc | 1.7B | -11.7x | --- |
Morphic Holding Inc | 1.7B | -9.8x | --- |
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 159.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.55 |
Book Value | $2.95 |
P/E Ratio | -6.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.